← Library
A cosmetic ingredient, not regulated or approved as a drug. This page is educational information only, not medical advice.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Acetyl tetrapeptide-9

Cosmetic ingredient

Cosmetic signal peptide

Also known as: Dermican, N-Acetyl-gln-asp-val-his, LS 9745, LS-9745, Acetyl tetrapeptide-9(Dermican LS 9837)

Evidence score
41/ 100
Emerging evidence

Early evidence, mostly unproven in humans

  • Regulatory standing. Cosmetic ingredient, not regulated as a drug
  • Limited human data. Some human data exists, not conclusive
  • Registered human trials. 1 registered study on ClinicalTrials.gov
  • 1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Acetyl tetrapeptide-9, sold under the trade name Dermican, is a small synthetic peptide used as an ingredient in topical skin care products. It is marketed as a signal peptide that may encourage skin cells to produce lumican and collagen, structural components of the skin's supporting matrix. This mechanism is based largely on manufacturer and laboratory data.

What the evidence shows

Automatic summaryLimited human data

It is regulated as a cosmetic ingredient, not a drug, and is not FDA-approved for any medical use. Human evidence is very thin, with one registered trial and one published paper found, so any effects on skin firmness or aging remain unestablished.

Key facts

Molecular formula
C22H33N7O9
Molecular weight
539.5 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

1registered studies
Nonemost advanced phase
1completed (sample)
0recruiting (sample)

Pilot Trial to Assess the Performance and Tolerance of mRDX-02-17 Dermal Filler in the Facial Rejuvenation

CompletedNCT03537456

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

1papers referencing Acetyl tetrapeptide-9

Real World Case Series: Integrated Skincare With Advanced RGN-6 Serum.

J Cosmet Dermatol2025

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.